ID: MRFR/Pharma/2648-CR | 61 Pages | Published By Rahul Gotadki on July 2019
The mitochondrial myopathy diagnosis & treatment market is expected to reach USD 31.68 Million by 2030 at 9.20% CAGR during the forecast period 2022-2030.
The mitochondrial myopathy treatment provides relief from mitochondrial myopathies such as Barth syndrome, chronic progressive external ophthalmoplegia (CPEO), Kearns-Sayre syndrome (KSS), etc. There exists no cure for the mitochondrial myopathy, although many drugs are in the pipeline, and few have received fast track approval and orphan drug status. The factors such as rising number of screening services for mitochondrial disorders, a growing number of mitochondrial myopathy cases, increased government funding, and incentives for rare genetic diseases are driving the market for mitochondrial myopathy diagnosis & treatment. However, inadequate treatment options and the absence of curative treatment have constrained the market. The treatment options have been divided into curative and symptomatic management of conditions associated with mitochondrial myopathies such as stroke and cardiac symptoms.
Mitochondrial myopathy is a rare mutational disease, and at present, there is no concrete treatment available for the disease. However, there are few diagnostic tests available in the mitochondrial myopathies treatment market, which are the only saving grace for the mitochondrial myopathy diagnosis & treatment market at present. There are certain factors which drive the growth of the market. These include a rise in the number of mitochondrial myopathy patients, development in the disease screening process and testing services, lucrative incentives for the rare genetic diseases, and government funding and support for the development of the treatment options.
Further, rising number of screening and a growing number of mitochondrial myopathy casesfor example, in the US, new-born screening is performed on every infant regardless of the parent’s health insurance status or paying ability with some states not even charging the nominal fees for the testing. Any other expenses are covered by most private health insurance plans and the Children's Health Insurance Program (CHIP) and Medicaid both cover the cost. Thus, rising screening both due to government regulations and increasing insurance penetration is estimated to drive the future growth of mitochondrial myopathies treatment market.
On the other hand, poor treatment options and unavailability of the curative treatment for the mitochondrial myopathy, lack of awareness, and a high number of the underdiagnosed population are some of the factors which hinder the growth of the mitochondrial myopathy diagnosis & treatment market.
Figure 1: - Global Mitochondrial Myopathy Diagnosis & Treatment Share, by Region 2017 (%)
Sources: WHO, Centers for Medicare & Medicaid Services, Annual Reports, Press Release, White Paper, and Company Presentation
The mitochondrial myopathy diagnosis & treatment market has been segmented based on type, services, diagnostic test, therapy. On the basis the type, the mitochondrial myopathies treatment market has been segregated into mitochondrial, encephalomyopathy, lactic acidosis, and stroke-like episodes, progressive external ophthalmoplegia, myoclonic epilepsy with ragged red fibres, mitochondrial neurogastrointestinal encephalopathy syndrome, Kearns–Sayre syndrome, mitochondrial DNA depletion syndrome, Pearson syndrome, Leigh syndrome, neuropathy, ataxia, and retinitis pigmentosa. On the basis of diagnostic tests, the market has been bifurcated into genetic tests, muscle biopsy, biochemical test. Based on therapy, the market has been divided into supportive therapy and targeted therapy.
The mitochondrial myopathy diagnosis & treatment market has been segmented on the basis of regions into the Americas, Europe, Asia-Pacific, and Middle East & Africa. Among these has captured the whole market of mitochondrial myopathy at present as there are no targeted therapies available in the market. There are few molecules under clinical development for the targeted treatment of the mitochondrial myopathy, which is expected to be available in the market after 2021. However, supportive therapy will continue to dominate the global mitochondrial myopathies treatment market until the availability of concrete treatment for the disease.
Americas mitochondrial myopathies treatment market is the largest market for the diagnosis and treatment of mitochondrial myopathy. Advanced healthcare services, state of the art healthcare infrastructure, availability of the better healthcare services and outcomes, development in the genetic testing spectrum, high awareness about the mitochondrial diseases among the population, efforts taken by various organization for spreading the awareness about such rare disease conditions. All these factors culminate to make the American region the largest market in the world. Some of the companies such as GeneDx and ARUP laboratories, among others are involved in the genetic testing of the mitochondrial diseases, including myopathy. Moreover, few companies such as Stealth Biotherapeutics are engaged in the development of the novel drugs for the targeted therapies for the mitochondrial myopathies.
Market Segmentation and Key Market Players
Mitochondrial Myopathy Diagnosis & Treatment Market, by Type
Mitochondrial Myopathy Diagnosis & Treatment Market, by Diagnostic Test
Mitochondrial Myopathy Diagnosis & Treatment Market, by Therapy
Mitochondrial Myopathy Diagnosis & Treatment Market, by Key Players
|Market Size||31.68 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Diagnostic Test, Therapy|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Stealth Biotherapeutics, Khondrion BV, NeuroVive Pharmaceutical AB, Reata Pharmaceuticals Inc., GeneDx, Mitobridge, Centogene AG, and Ixchel Pharma.|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||Rising prevalence and higher awareness regarding the disease and advancements|
Mitochondrial myopathy diagnosis & treatment market projected to grow at approximately 9.20% CAGR during the assessment period.
The valuation of the global mitochondrial myopathy diagnosis & treatment market is estimated to increase to USD 31.68 Million by the end of 2030.
Rising prevalence and higher awareness regarding the disease and advancements in diagnosis & treatment process are major tailwinds pushing the growth of the global mitochondrial myopathy diagnosis & treatment market.
North America holds the largest share in the global mitochondrial myopathy diagnosis & treatment market, followed by Europe and the Asia Pacific, respectively.
Stealth Biotherapeutics, AbbVie Inc., Khondrion BV, Centogene AG, NeuroVive Pharmaceutical AB, Ixchel Pharma, Reata Pharmaceuticals Inc., Khondrion BV, GeneDx, Mitobridge, and Centogene AG, are some of the top players operating in the global mitochondrial myopathy diagnosis & treatment market.